Clinical trials: Intravenous Infusions
Intravenous Access, Medical Device
Safe-Infusion Study
Around 1.5 billion peripheral intravenous catheters (PIVCs) are sold yearly, with up to 90% of hospitalized patients receiving one, yet failure rates can reach 69%, often due to phlebitis, infiltration, occlusion, or…
- Trial name
- NCT06727240
- Testing
- Intervention
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 548 people
- Sponsor
- Interlinked AB
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124
In this early phase clinical research study, the investigational drug will be administered to 64 healthy volunteers in a double-blind, placebo-controlled manner, at a one research center.
- Trial name
- NCT04728061
- Testing
- Gen1E-1124
- Where
- New Zealand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GEn1E Lifesciences
Normal Healthy Subjects
A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization
This is a randomized, placebo- and positive-controlled (moxifloxacin), 3-period, 3-way crossover thorough QT study, which includes a Screening Period, Treatment Periods (1 through 3), and a Follow-up Visit.
- Trial name
- NCT01941446
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tetraphase Pharmaceuticals, Inc
End Stage Renal Disease on Dialysis (Diagnosis)
Plasma Amino Acid Levels After Protein Ingestion or Amino Acid Injection During Dialysis
The aim of the study is to compare intradialytic plasma kinetics of amino acids after administration per os of Renoral or intravenous administration of amino acids in patients with end-stage renal disease treated with…
- Trial name
- NCT03807583
- Testing
- Aminoven 10%, RENORAL
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Indigo Therapeutics
Advanced Tumors
Study of CPI-100 in Patients With Advanced Tumors
This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
- Trial name
- NCT03781362
- Testing
- CPI-100, Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Dyskinesias, Movement Disorders
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.
- Conditions
- Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases
- Trial name
- NCT04912115
- Testing
- Ketamine, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- PharmaTher Inc.
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Cirrhosis
Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects
The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects.
- Trial name
- NCT01164332
- Testing
- NRL972
- Where
- Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Norgine
Psoriasis
Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.
- Trial name
- NCT02630901
- Testing
- PRX003
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Prothena Biosciences Limited
Gastrointestinal Cancer, Lung Cancer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
This is a study in adults from Asia with different types of advanced cancer (solid tumours). People can join the study if they have cancer of the stomach, large bowel and rectum, pancreas, liver, head and neck or non-small cell…
- Conditions
- Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06091930
- Testing
- BI 765049, Ezabenlimab
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Dehydration
Subcutaneous Rehydration Compared to Intravenous Rehydration
Randomized (1:1 ratio) study of subcutaneous (SC) versus intravenous (IV) fluid rehydration in mildly to moderately dehydrated pediatric patients.
- Trial name
- PEDs-II (NCT00773175)
- Testing
- recombinant human hyaluronidase
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Halozyme Therapeutics
Marburg Virus Disease
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
- Trial name
- NCT03800173
- Testing
- galidesivir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Refractory Solid Tumors, Lymphoma
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
This is a Phase I continuous infusion study designed to explore if constant concentration over time adds to the effectiveness of terameprocol without increasing toxicity. It will also explore weekly dosing as an option.
- Trial name
- NCT00664586
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Erimos Pharmaceuticals
Chronic Spontaneous Urticaria
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria
This is a phase II, double-blind, randomized, parallel group, placebo-controlled study to evaluate the pharmacodynamics, pharmacokinetics, efficacy, and safety of 2-dose UB-221 IV infusion as an add-on therapy in patients with…
- Trial name
- NCT05298215
- Testing
- UB-221, sterile saline solution
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- United BioPharma
Healthy
Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b
The proposed study is not hypothesis testing but is intended to explore the effects of different ethnic groups (Caucasian, Japanese, Chinese, and Korean) on the PK (pharmacokinetic), PD (pharmacodynamic), and safety of an IV…
- Trial name
- NCT02647307
- Testing
- DS-1040b
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Healthy
A Study of JNJ-80202135 in Healthy Chinese Adult Participants
The purpose of this study is to assess the pharmacokinetic (PK) of nipocalimab following single intravenous (IV) administration in healthy Chinese participants.
- Trial name
- NCT05151692
- Testing
- Nipocalimab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Neurodegenerative Diseases
A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
Up to 80 healthy adult males, ≥ 18 and ≤ 55 years of age, are planned to be enrolled in the study. The study will consist of 8 cohorts (Cohorts 1 to 8, 1 cohort per dose level).
- Trial name
- NCT05143463
- Testing
- NS101 IV infusion
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Neuracle Science Co., LTD.
Rheumatoid Arthritis
Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis
This is a phase 1, randomized, placebo-controlled, double-blind, single-dose, clinical trial examining the safety and biological effects of allogeneic fresh human umbilical cord tissue-derived mesenchymal stem cell product…
- Trial name
- NCT03828344
- Testing
- hUC-MSC suspension
- Volunteers
- 16 people
- Sponsor
- Baylx Inc.
Fabry Disease
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have…
- Trial name
- NCT03614234
- Testing
- pegunigalsidase alfa
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 29 people
- Sponsor
- Chiesi Farmaceutici S.p.A.